Table 4 Characteristics of cancers detected by supplemental MRI (n = 36)
| Â | Median (IQR) or n (%) |
|---|---|
MRI | |
 Lesion diameter, mm, median (IQR) | 12 (8–18) |
 Multiple lesions, n (%) | |
 No | 29 (81%) |
 2 lesions | 5 (14%) |
 ≥3 lesions | 2 (6%) |
Biopsy (n = 36) | |
 Invasiveness, n (%) | |
 In situ only | 4 (11.1%) |
 Invasive only | 27 (75%) |
 In situ and invasive | 5 (13.9%) |
 Histology, n (%) | |
 Ductal | 30 (83.3%) |
 Lobular | 5 (13.9%) |
 Mucinous | 1 (2.8%) |
 Grade, n (%) (1 missing) | |
 1 | 6 (17%) |
 2 | 26 (74.3%) |
 3 | 3 (8.6%) |
 Receptor expression, n (%) | |
 HR+ | 33 (91.7%) |
 HER2+/HR− | 0 (0%) |
 HER2−/HR− | 3 (8.3%) |
 Ki-67, n (%) (5 missing) | |
 Low | 5 (14%) |
 Intermediate | 22 (61%) |
 High | 4 (11%) |
 Lymph node, n (%) | |
 No biopsy | 31 (86%) |
 Metastasis | 2 (6%) |
 No metastasis | 3 (8%) |
Surgical specimen (n = 35; 1 in neoadjuvant therapy) | |
 Lesion diameter, mm, median (IQR) | 13 (8–17) |
 Total extent, mm, median (IQR) | 15 (12–35) |
 Total extent, mm, min and max | 7 and 85 |
 Multiple lesions, n (%) | |
 No | 32 (89%) |
 2 lesions | 2 (6%) |
 ≥3 lesions | 2 (6%) |
 Invasiveness, n (%) | |
 In situ only | 5 (13.8%) |
 In situ and invasive | 22 (61%) |
 Invasive only | 8 (22.2%) |
 Histology, n (%) | |
 Ductal | 27 (75%) |
 Lobular | 6 (16.7%) |
 Mucinous | 1 (2.78%) |
 Grade, n (%) | |
 1 | 3 (8.3%) |
 2 | 27 (75%) |
 3 | 5 (13.9%) |
 Receptor expression, n (%) | |
 HR+ | 33 (91.7%) |
 HER2+/HR− | 0 (0%) |
 HER2−/HR− | 2 (5.6%) |
 Ki-67, n (%) | |
 Low | 10 (27.8%) |
 Intermediate | 14 (38.9%) |
 High | 6 (16.7%) |
 Lymph node, n (%) | |
 None excised | 14 (38.9%) |
 Metastasis | 3 (8.3%) |
 No metastasis | 19 (52.8%) |
